Molecular pathological insights reveal a high number of unfavorable risk patients among children treated for medulloblastoma and CNS-PNET in Oslo 2005-2017.
Pitt NiehusmannEinar StensvoldHenning LeskeTorsten PietschTobias GoschzikGerrit H GielenBernt Due-TønnessenRadek FričYngvar NilssenPetter BrandalPublished in: Pediatric blood & cancer (2022)
Molecular-based risk stratification of standard-risk non-WNT/non-SHH medulloblastoma enabled superior identification of medulloblastomas with dismal prognosis. Our cohort demonstrated a significantly increased fraction of standard-risk non-WNT/non-SHH medulloblastoma with molecular high-risk profile compared to other studies, which might have contributed to previously reported unfavorable outcome data.
Keyphrases
- end stage renal disease
- stem cells
- cell proliferation
- young adults
- ejection fraction
- single molecule
- chronic kidney disease
- blood brain barrier
- gene expression
- genome wide
- peritoneal dialysis
- machine learning
- electronic health record
- big data
- patient reported outcomes
- deep learning
- artificial intelligence
- bioinformatics analysis